{"analyses":[{"ciLowerLimit":"0.747","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.953","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0061","paramType":"Hazard Ratio (HR)","paramValue":"0.844","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"4.8","value":"4.3"},{"groupId":"OG001","lowerLimit":"3.3","upperLimit":"4.1","value":"3.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"545"},{"groupId":"OG001","value":"548"}],"units":"Participants"}],"description":"TTF is defined as the time from the date of randomization until the date of the first radiographic documentation of PD, death from any cause, discontinuation of treatment for any reason, or initiation of new cancer therapy. Participants who withdrew from the study for reasons other than progression or death were censored at the date of study withdrawal. Participants who did not meet any of the criteria for treatment failure were censored at their date of last contact in the study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Necitumumab + Gemcitabine + Cisplatin\n\nNecitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.\n\nContinues until progressive disease, toxicity, noncompliance, or withdrawal.\n\nGemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.\n\nContinues for a maximum of six cycles.\n\nCisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.\n\nContinues for a maximum of six cycles.","id":"OG000","title":"Necitumumab + Gemcitabine + Cisplatin"},{"description":"Gemcitabine + Cisplatin\n\nGemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.\n\nContinues for a maximum of six cycles.\n\nCisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.\n\nContinues for a maximum of six cycles.","id":"OG001","title":"Gemcitabine + Cisplatin"}],"paramType":"MEDIAN","populationDescription":"All randomized participants. Censored participants: Necitumumab + Gemcitabine + Cisplatin = 16, Gemcitabine + Cisplatin =20","reportingStatus":"POSTED","timeFrame":"Randomization to Measured Progressive Disease, Death From Any Cause, Discontinuation of Treatment or Initiation of New Anticancer Therapy (Up to 31 Months)","title":"Time to Treatment Failure (TTF)","type":"SECONDARY","unitOfMeasure":"Months"}